Related Experiment Video
Updated: Jun 20, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Cellular immunotherapy in melanoma: the next frontier in cancer treatment
Anna-Lena Wien1, Angeliki Stamtsis-Datsi2
1Institute for Transplantation Diagnostics and Cell Therapeutics, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Gebäude 14.88 Moorenstr. 5, Düsseldorf, 40225, Germany.
Abstract:
Therapy-resistant melanoma remains a major clinical challenge despite advances with immune checkpoint inhibitors and targeted therapies, as most patients ultimately exhibit primary or acquired resistance and progress through multiple toxic treatment lines with limited durable benefit. This resistance reflects not only T-cell dysfunction but also a profound quantitative deficit of tumor-reactive lymphocytes, compounded by myeloid- and Treg-mediated immunosuppression, impaired antigen presentation, and tumor dedifferentiation programs generating a cold tumor microenvironment. Cellular immunotherapies aim to overcome these barriers by supplying or priming new tumor-reactive repertoires while reshaping the tumor microenvironment and restoring durable immunity. Dendritic-cell vaccines safely induce broad, long-lived responses but show modest activity as monotherapy in advanced disease. Tumor-infiltrating lymphocyte therapy directly replaces the missing tumor-specific compartment and has demonstrated clinically meaningful response rates in checkpoint-refractory melanoma, though at the cost of complex, intensive manufacturing and conditioning requirements. Genetically engineered TCR-T and CAR T/CAR NK therapies provide programmable specificity but remain constrained by antigen selection, toxicity risks, and limited persistence in solid tumors. NK-cell platforms offer HLA-independent, off-the-shelf potential but require further optimization for trafficking, persistence, and resistance to suppression. Overall, rational combinations - particularly DC-priming integrated with adoptive cell therapy - represent the most promising path to durable tumor control in treatment-refractory melanoma.
Insights
Therapy-resistant melanoma is a challenge due to immune evasion. Cellular immunotherapies, especially combinations like dendritic-cell priming with adoptive cell therapy, show promise for durable tumor control.
Area of Science:
- Oncology
- Immunology
- Cancer Therapy
Background:
- Therapy-resistant melanoma presents a significant clinical hurdle, with many patients experiencing limited durable benefit from current treatments like immune checkpoint inhibitors and targeted therapies.
- Resistance mechanisms include T-cell dysfunction, reduced tumor-reactive lymphocytes, immunosuppression by regulatory T-cells and myeloid cells, poor antigen presentation, and tumor dedifferentiation leading to a "cold" tumor microenvironment.
Purpose of the Study:
- To review the landscape of cellular immunotherapies for overcoming resistance in advanced melanoma.
- To evaluate the potential and limitations of various cellular immunotherapy strategies, including dendritic-cell vaccines, tumor-infiltrating lymphocytes, and engineered T-cell and NK-cell therapies.
- To identify promising combination strategies for achieving durable tumor control in treatment-refractory melanoma.
Main Methods:
- Review of current literature on cellular immunotherapies for melanoma.
- Analysis of the mechanisms of resistance in melanoma.
- Evaluation of the efficacy, manufacturing complexity, and toxicity profiles of different cellular immunotherapy approaches.
Main Results:
- Dendritic-cell vaccines induce robust immune responses but have modest monotherapy activity.
- Tumor-infiltrating lymphocyte therapy shows clinical responses in refractory melanoma but requires intensive manufacturing and conditioning.
- Engineered T-cell and NK-cell therapies offer programmable specificity but face challenges with antigen selection, toxicity, and persistence in solid tumors.
Conclusions:
- Rational combinations of cellular immunotherapies, particularly those integrating dendritic-cell priming with adoptive cell therapy, represent the most promising strategy for durable tumor control in patients with treatment-refractory melanoma.
- Addressing T-cell dysfunction, lymphocyte deficits, and the immunosuppressive tumor microenvironment is crucial for improving outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...